IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025

Aggregated presentation by day and by market

Statement of transactions in own shares from July 28th to August 1st 2025

       
Name of the issuer Identity code of the issuer

(Legal Entity Identifier) 		Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market         (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 28/07/2025 FR0010259150 3765 113,4151394 CCXE
IPSEN 549300M6SGDPB4Z94P11 28/07/2025 FR0010259150 2000 113,89735 XPAR
IPSEN 549300M6SGDPB4Z94P11 29/07/2025 FR0010259150 2875 111,873913 CCXE
IPSEN 549300M6SGDPB4Z94P11 29/07/2025 FR0010259150 1893 112,1541469 XPAR
IPSEN 549300M6SGDPB4Z94P11 30/07/2025 FR0010259150 586 111,6720137 CCXE
IPSEN 549300M6SGDPB4Z94P11 30/07/2025 FR0010259150 2369 111,9968763 XPAR
IPSEN 549300M6SGDPB4Z94P11 31/07/2025 FR0010259150 1800 103,8611111 AQEU
IPSEN 549300M6SGDPB4Z94P11 31/07/2025 FR0010259150 6515 104,3231926 CCXE
IPSEN 549300M6SGDPB4Z94P11 31/07/2025 FR0010259150 1000 104 TQEX
IPSEN 549300M6SGDPB4Z94P11 31/07/2025 FR0010259150 5814 104,750946 XPAR
IPSEN 549300M6SGDPB4Z94P11 01/08/2025 FR0010259150 3000 102,7121 CCXE
IPSEN 549300M6SGDPB4Z94P11 01/08/2025 FR0010259150 1945 103,1841645 XPAR
      TOTAL 33 562 107,5018  

Attachment



EN
05/08/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

10h / 32m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

10h / 32m 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch